Our top pick for
NanoVibronix, Inc is a medical devices business based in the US. NanoVibronix shares (NAOV) are listed on the NASDAQ and all prices are listed in US Dollars. NanoVibronix employs 10 staff and has a trailing 12-month revenue of around USD$620,000.
|Latest market close||USD$0.8179|
|52-week range||USD$0.535 - USD$3.015|
|50-day moving average||USD$0.7857|
|200-day moving average||USD$1.1376|
|Wall St. target price||USD$10.5|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.921|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-07)||-8.10%|
|1 month (2020-12-17)||-5.34%|
|3 months (2020-10-16)||22.62%|
|6 months (2020-07-17)||-54.56%|
|1 year (2020-01-17)||-70.44%|
|2 years (2019-01-17)||-75.94%|
|3 years (2018-01-17)||4.45|
|5 years (2016-01-13)||4.15|
|Gross profit TTM||USD$281,000|
|Return on assets TTM||-77%|
|Return on equity TTM||-164.2%|
|Market capitalisation||USD$14.7 million|
TTM: trailing 12 months
There are currently 152,395 NanoVibronix shares held short by investors – that's known as NanoVibronix's "short interest". This figure is 74.4% up from 87,371 last month.
There are a few different ways that this level of interest in shorting NanoVibronix shares can be evaluated.
NanoVibronix's "short interest ratio" (SIR) is the quantity of NanoVibronix shares currently shorted divided by the average quantity of NanoVibronix shares traded daily (recently around 662586.95652174). NanoVibronix's SIR currently stands at 0.23. In other words for every 100,000 NanoVibronix shares traded daily on the market, roughly 230 shares are currently held short.
However NanoVibronix's short interest can also be evaluated against the total number of NanoVibronix shares, or, against the total number of tradable NanoVibronix shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NanoVibronix's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 NanoVibronix shares in existence, roughly 10 shares are currently held short) or 0.0114% of the tradable shares (for every 100,000 tradable NanoVibronix shares, roughly 11 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against NanoVibronix.
Find out more about how you can short NanoVibronix stock.
We're not expecting NanoVibronix to pay a dividend over the next 12 months.
Over the last 12 months, NanoVibronix's shares have ranged in value from as little as $0.535 up to $3.015. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NanoVibronix's is -0.0835. This would suggest that NanoVibronix's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, NanoVibronix has bucked the trend.
NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its principal products include UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device, which facilitates tissue regeneration and wound healing. The company sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, India, and internationally. NanoVibronix, Inc. was founded in 2003 and is based in Elmsford, New York.
Everything we know about the Home Point Capital Inc IPO, plus information on how to buy in.
Everything we know about the ALFI INC IPO, plus information on how to buy in.
Steps to owning and managing CDAY, with 24-hour and historical pricing before you buy.
Steps to owning and managing CPF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CFFI, with 24-hour and historical pricing before you buy.
Steps to owning and managing BPY, with 24-hour and historical pricing before you buy.
Steps to owning and managing BANF, with 24-hour and historical pricing before you buy.
Steps to owning and managing AVDL, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEAM, with 24-hour and historical pricing before you buy.
Steps to owning and managing AUDC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.